Australia-wide dispatch

Quantified
Peptides
Tesamorelin + Ipamorelin Stack 12mg — research peptide blend in a single lyophilised vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Stacks & Blends

Tesamorelin + Ipamorelin Stack

Tesamorelin + Ipamorelin Stack. Supplied as a lyophilised powder in 12mg vials.

Product information

About Tesamorelin + Ipamorelin Stack

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

The Tesamorelin + Ipamorelin blend combines two complementary growth hormone secretagogues that act through distinct receptor mechanisms. Tesamorelin (GHRH analogue) stimulates pituitary GH release via GHRH receptor agonism, while Ipamorelin (GHS-R1a agonist) promotes GH secretion through ghrelin receptor pathways.

The combination is researched for potential synergistic effects on GH pulsatility and the GH/IGF-1 axis. Ipamorelin's selectivity for GH secretion without cortisol or prolactin elevation makes it a preferred partner in dual-secretagogue research protocols.

Composition
Tesamorelin 10mg + Ipamorelin 2mg (lyophilised blend)
Type
Dual GH secretagogue research stack
Research Areas
Synergistic GH pulsatility, GH/IGF-1 axis, metabolic research
Tesamorelin
10mg — GHRH receptor agonist (44 AA analogue)
Ipamorelin
2mg — GHS-R1a agonist (selective GH secretagogue)
Total Dosage
12mg per vial
GH Pathway
GHRH-R + GHS-R1a dual activation
Half-life (CJC)
~30 min (Tesamorelin, research models)
Half-life (Ipa)
~2 hours (Ipamorelin, research models)
Primary Research
GH/IGF-1 axis, metabolic effects
  1. 01Dual Pathway GH StimulationTesamorelin activates GHRH receptors to stimulate pituitary GH release, while Ipamorelin agonises the ghrelin receptor (GHS-R1a) via a complementary mechanism. Research examines whether co-activation of both pathways produces additive or synergistic GH pulsatility.
  2. 02Ipamorelin Selectivity ProfileIpamorelin is studied for its high selectivity — stimulating GH release without significantly elevating cortisol, prolactin, or ACTH. Combined with Tesamorelin, research has examined whether this selectivity profile is maintained in the blend vs. non-selective secretagogues.
  3. 03GH Pulsatility & IGF-1 ResearchCombined GH secretagogue protocols are investigated for their ability to restore or amplify physiological GH pulsatility. Research has examined IGF-1 response profiles, GH pulse amplitude, and frequency in animal models using this dual-pathway approach.

References

  1. 1Falutz J et al. Tesamorelin metabolic effects. NEJM. 2007;357(23):2359-70.
  2. 2Raun K et al. Ipamorelin — selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552-561.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+Tesamorelin
  4. 4PubMed: pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+GH+secretagogue

Composition

What’s inside

Supplied as a single vial. Doses are per vial, not per component vial.

  1. 01Tesamorelin10mg
  2. 02Ipamorelin2mg

Other stacks